Bulletin
Investor Alert

London Markets Close in:

Market Pulse Archives

Jan. 16, 2019, 4:49 p.m. EST

Adamis stock surges on release of EpiPen alternative

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Adamis Pharmaceuticals Corp. (ADMP)
  • X
    Novartis AG ADR (NVS)

or Cancel Already have a watchlist? Log In

By Wallace Witkowski

Adamis Pharmaceuticals Corp. /zigman2/quotes/205166351/composite ADMP -1.77% shares surged in the extended session Wednesday after the biotech company said its partner Sandoz Inc. launched an alternative to epinephrine auto-injectors like Mylan NV's EpiPen. Adamis shares rallied 14% after hours, after closing up 4.8% at $2.63 in regular trading Wednesday. Adamis said that Sandoz, which is part of Novartis AG /zigman2/quotes/203243705/composite NVS -0.71% , launched Symjepi, a single-dose treatment for allergic reactions including anaphylaxis. "With recent news of epinephrine product shortages in the U.S., we worked together with Sandoz in getting this potentially life-saving quality product into the market as quickly as possible," said Dennis Carlo, chief executive at Adamis, in a statement.

/zigman2/quotes/205166351/composite
US : U.S.: Nasdaq
$ 0.40
-0.0072 -1.77%
Volume: 84,153
May 25, 2022 11:21a
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$60.85 million
Rev. per Employee
$147,245
loading...
/zigman2/quotes/203243705/composite
US : U.S.: NYSE
$ 91.28
-0.65 -0.71%
Volume: 1.37M
May 25, 2022 11:22a
P/E Ratio
8.48
Dividend Yield
2.37%
Market Cap
$200.43 billion
Rev. per Employee
$496,017
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.